CRL — Charles River Laboratories Inte

Is CRL overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of October 3, 2026

Charles River Laboratories Inte (CRL) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Diagnostics & Research) last closed at $290.19. The rating moved from Neutral to Overbought on October 3, 2026.

See all overbought Healthcare stocks →

AI analysis

Charles River Laboratories Inte (CRL) is well positioned as a diversified CRO and preclinical services provider to capture ongoing demand from biologics, rare-disease and advanced-therapy programs. The business benefits from recurring contract flows, deep technical capabilities, and cross-selling potential that support steady revenue visibility and margin improvement as utilization rises. Near-term market caution and constrained biotech funding could moderate early-stage service growth, but late-stage clinical and manufacturing needs reinforce medium-term revenue opportunities. Key sensitivities include client spending cycles, competitive pricing pressure, and policy-driven impacts on pharmaceutical budgets. Social sentiment is limited but recent company filings are neutral-to-positive; absent a major macro shock, upside is driven by continued outsourcing demand and margin expansion scenarios.

Key factors

  • Leading provider of preclinical, discovery and CRO services with broad end‑market exposure to biopharma R&D, benefiting from secular growth in biologics, gene/cell therapy and specialty pharma
  • Recurring revenue model and long-term client relationships provide revenue visibility and potential margin leverage as utilization and cross-selling improve
  • Positive industry tailwinds from late-stage biologics and rare-disease therapy wins that increase outsourced R&D and specialized testing demand
  • Integrated service offering across small molecule, biologics and advanced therapies differentiates versus competitors and supports pricing power for complex programs
  • Recent SEC filing activity and steady demand signals support ongoing contract wins and commercial momentum despite market volatility

Risks

  • Macro-driven risk aversion and tighter capital markets (IPO window cooling) could reduce biotech client funding and slow early-stage outsourcing demand
  • Policy and payer pressure (e.g., Medicare drug-price negotiation) that compresses client pricing and program budgets, indirectly reducing CRO spending
  • Intense competition from large CROs and integrated service providers that can pressure pricing and market share
  • Operational risks including supply-chain disruptions, capacity constraints for specialized assays or biologics support, and integration risks from acquisitions
  • Client concentration on large programs and wins/losses of a few major contracts creating revenue volatility

See today's live rating, score and targets

Members see the live hourly rating for CRL — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.